Publications
Review & Commentary
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group
(2010). Clin Exp Immunol, 160 (2), 176-184. , PMID: 20629979, PMCID: 2857940
Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, ITN/JDRF Type 1 Diabetes Combination Therapy Assessment Group
[Reprint] [PubMed]
[Citation View]
Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, ITN/JDRF Type 1 Diabetes Combination Therapy Assessment Group (2010). Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol, 160 (2), 176-184.
Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia
(2010). Curr Opin Organ Transplant, 15 (4), 441-448. http://dx.doi.org/10.1097/MOT.0b013e32833bd371, PMID: 20631613
Turka LA, Wood K, Bluestone JA
[PubMed]
[Citation View]
Turka LA, Wood K, Bluestone JA (2010). Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant, 15 (4), 441-448.
Immune Tolerance Network at 10 years: Tolerance research at the bedside
(2010). Nat Rev Immunol, 10 (11), 797-803. http://dx.doi.org/10.1038/nri2869, PMID: 20972473
Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St. Clair EW, Turka LA
[Reprint] [PubMed]
[Citation View]
Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St. Clair EW, Turka LA (2010). Immune Tolerance Network at 10 years: Tolerance research at the bedside. Nat Rev Immunol, 10 (11), 797-803.
Adding value to liver (and allograft) biopsy evaluation using a combination of multiplex quantum dot immunostaining, high-resolution whole-slide digital imaging, and automated image analysis
(2010). Clin Liver Dis, 14 (4), 669-685. http://dx.doi.org/10.1016/j.cld.2010.07.004, PMID: 21055689
Isse K, Grama K, Abbott IM, Lesniak A, Lunz J, Lee WM, Specht S, Corbitt N, Mizuguchi Y, Roysam B, Demetris AJG
[PubMed]
[Citation View]
Isse K, Grama K, Abbott IM, Lesniak A, Lunz J, Lee WM, Specht S, Corbitt N, Mizuguchi Y, Roysam B, Demetris AJG (2010). Adding value to liver (and allograft) biopsy evaluation using a combination of multiplex quantum dot immunostaining, high-resolution whole-slide digital imaging, and automated image analysis. Clin Liver Dis, 14 (4), 669-685.
Marking a path to transplant tolerance
(2008). J Clin Invest, 118 (8), 2684-. http://dx.doi.org/10.1172/JCI36552, PMID: 18654643, PMCID: 2483691
Seyfert-Margolis V, Turka LA
[Reprint] [PubMed]
[Citation View]
Seyfert-Margolis V, Turka LA (2008). Marking a path to transplant tolerance. J Clin Invest, 118 (8), 2684-.
New reagents on the horizon for immune tolerance
(2007). Ann Rev Med, 58 (0), 329–46. , PMID: 16987079
St. Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J
[Reprint] [PubMed]
[Citation View]
St. Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J (2007). New reagents on the horizon for immune tolerance. Ann Rev Med, 58 (0), 329–46.
Allorecognition and the alloresponse: clinical implications
(2007). Tissue Antigens, 69 (6), 545-56. , PMID: 17498264
Afzali B, Lechler RI, Hernandez-Fuentes MP
[Reprint] [PubMed]
[Citation View]
Afzali B, Lechler RI, Hernandez-Fuentes MP (2007). Allorecognition and the alloresponse: clinical implications. Tissue Antigens, 69 (6), 545-56.
Role of autoantibodies in type 1 diabetes
(2007). Front Biosci, 12 (0), 1889-1898. , PMID: 17127428
Miao D, Yu L, Eisenbarth GS
[Reprint] [PubMed]
[Citation View]
Miao D, Yu L, Eisenbarth GS (2007). Role of autoantibodies in type 1 diabetes. Front Biosci, 12 (0), 1889-1898.
Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity
(2004). Clin Immunol, 111 (3), 225-33. , PMID: 15183143
Devendra D, Eisenbarth GS
[Reprint] [PubMed]
[Citation View]
Devendra D, Eisenbarth GS (2004). Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol, 111 (3), 225-33.
Type 1 diabetes: recent developments
(2004). BMJ, 328 (7442), 750-754. , PMID: 15044291, PMCID: PMC381328
Devendra D, Liu E, Eisenbarth GS
[Reprint] [PubMed]
[Citation View]
Devendra D, Liu E, Eisenbarth GS (2004). Type 1 diabetes: recent developments. BMJ, 328 (7442), 750-754.
Autoimmune polyendocrine syndromes
(2004). New Engl J Med, 350 (20), 36-47. , PMID: 15141045
Eisenbarth GS, Gottlieb PA
[Reprint] [PubMed]
[Citation View]
Eisenbarth GS, Gottlieb PA (2004). Autoimmune polyendocrine syndromes. New Engl J Med, 350 (20), 36-47.
Disease prevention with islet autoantigens
(2004). Endocrinol Metab Clin North Am, 33 (1), 59-74. , PMID: 15053895
Eisenbarth G, Jasinski J
[Reprint] [PubMed]
[Citation View]
Eisenbarth G, Jasinski J (2004). Disease prevention with islet autoantigens. Endocrinol Metab Clin North Am, 33 (1), 59-74.
What impact will the Immune Tolerance Network have on the future treatment of allergic diseases?
(2004). Clin Exp Allergy, 34 (11), 1657-1659. , PMID: 15544586
Saxon, A
[Reprint] [PubMed]
[Citation View]
Saxon, A (2004). What impact will the Immune Tolerance Network have on the future treatment of allergic diseases?. Clin Exp Allergy, 34 (11), 1657-1659.
Clinical trials of transplant tolerance: slow but steady progress
(2003). Am J Transplant, 3 (7), 794-803. , PMID: 12814471
Matthews JB, Ramos E, Bluestone JA
[Reprint] [PubMed]
[Citation View]
Matthews JB, Ramos E, Bluestone JA (2003). Clinical trials of transplant tolerance: slow but steady progress. Am J Transplant, 3 (7), 794-803.
MHC multimers: expanding the clinical toolkit
(2003). Clin Immunol, 106 (1), 1-4. , PMID: 12584043
Nepom, GT
[Reprint] [PubMed]
[Citation View]
Nepom, GT (2003). MHC multimers: expanding the clinical toolkit. Clin Immunol, 106 (1), 1-4.
The Immune Tolerance Network: a new paradigm for developing tolerance-inducing therapies
(2002). J Allergy Clin Immunol, 110 (1), 17-23. , PMID: 12110811
Rotrosen D, Matthews JB, Bluestone JA
[Reprint] [PubMed]
[Citation View]
Rotrosen D, Matthews JB, Bluestone JA (2002). The Immune Tolerance Network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol, 110 (1), 17-23.
The Immune Tolerance Network: tolerance at the crossroads
(2001). Philos Trans R Soc Lond B Biol Sci, 356 (1409), 773-6. , PMID: 11375080, PMCID: PMC1088464
Bluestone JA, Matthews J
[Reprint] [PubMed]
[Citation View]
Bluestone JA, Matthews J (2001). The Immune Tolerance Network: tolerance at the crossroads. Philos Trans R Soc Lond B Biol Sci, 356 (1409), 773-6.
The Immune Tolerance Network and rheumatic disease: immune tolerance comes to the clinic
(2001). Arthritis Rheum, 44 (8), 1730-5. , PMID: 11508422
Diamond B, Bluestone J, Wofsy D
[Reprint] [PubMed]
[Citation View]
Diamond B, Bluestone J, Wofsy D (2001). The Immune Tolerance Network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum, 44 (8), 1730-5.
The Immune Tolerance Network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists
(2000). Clin Immunol, 96 (3), 171-3. , PMID: 10964534
Bluestone JA, Matthews JB
[Reprint] [PubMed]
[Citation View]
Bluestone JA, Matthews JB (2000). The Immune Tolerance Network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin Immunol, 96 (3), 171-3.